{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:11Z","timestamp":1790265371658,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ijantimicag.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T02:57:40Z","timestamp":1456369060000},"page":"269-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature"],"prefix":"10.1016","volume":"47","author":[{"given":"Konstantinos Z.","family":"Vardakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos J.","family":"Legakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Triarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0510","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0515","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0520","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10096-014-2124-9","article-title":"Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review","volume":"33","author":"Poulikakos","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0525","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2013.05.018","article-title":"What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review","volume":"42","author":"Parker","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0535","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0540","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0545","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/13543780902967624","article-title":"Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies","volume":"18","author":"Falagas","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0550","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/jac\/dkp288","article-title":"CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin","volume":"64","author":"Oteo","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0555","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0560","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.22815","article-title":"Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis","volume":"49","author":"Champion","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0565","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0570","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0575","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijantimicag.2013.02.018","article-title":"In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections","volume":"41","author":"Molina-Manso","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0580","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.medmal.2011.09.010","article-title":"Emergence of vancomycin-resistant Staphylococcus aureus identified in the Tlemcen University Hospital (North-West Algeria)","volume":"41","author":"Rebiahi","year":"2011","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0585","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-7796.148585","article-title":"Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer?","volume":"7","author":"Sultan","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0590","first-page":"728","article-title":"Current pattern of antibiotic resistance in Staphylococcus aureus clinical isolates and the emergence of vancomycin resistance","volume":"20","author":"Taj","year":"2010","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0595","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3855\/jidc.3766","article-title":"Frequency and antibiotic susceptibility patterns of urinary pathogens in male outpatients in Argentina","volume":"8","author":"Villar","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0600","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/ja.2010.105","article-title":"In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus","volume":"63","author":"Yu","year":"2010","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0605","doi-asserted-by":"crossref","first-page":"592.e1","DOI":"10.1016\/j.cmi.2015.01.028","article-title":"Correlation between clinical data and antibiotic resistance in coagulase-negative Staphylococcus species isolated from 68 patients with acute post-cataract endophthalmitis","volume":"21","author":"Chiquet","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0610","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijantimicag.2010.01.010","article-title":"Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0615","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10156-011-0212-7","article-title":"In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics","volume":"17","author":"Butcu","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0620","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0625","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2013.56","article-title":"Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10","volume":"66","author":"Pogue","year":"2013","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0630","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/fmb.13.31","article-title":"Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study","volume":"8","author":"Sahni","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0635","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-12-33","article-title":"Resistance profiles of urinary tract infections in general practice\u2014an observational study","volume":"12","author":"Schmiemann","year":"2012","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0640","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diagmicrobio.2013.07.012","article-title":"In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates","volume":"77","author":"Tang","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 6","key":"10.1016\/j.ijantimicag.2016.02.001_bib0645","doi-asserted-by":"crossref","first-page":"G18","DOI":"10.1016\/j.vaccine.2012.07.017","article-title":"Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study","volume":"30","author":"Charfi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0650","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7196\/SAMJ.6722","article-title":"Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa","volume":"103","author":"Lewis","year":"2013","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0655","first-page":"396","article-title":"Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul","volume":"24","author":"Tariq","year":"2014","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0660","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.medmal.2015.01.010","article-title":"Molecular characterization of extended spectrum \u03b2-lactamases produced by Klebsiella pneumoniae clinical strains from a Tunisian Hospital","volume":"45","author":"Alibi","year":"2015","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0665","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000339200","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline","volume":"21","author":"Al-Zarouni","year":"2012","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0670","first-page":"142","article-title":"In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon","volume":"60","author":"Araj","year":"2012","journal-title":"J Med Liban"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0675","first-page":"261","article-title":"Trend in the susceptibility of the most frequent bacterial pathogens isolated at Hospital General La Mancha Centro over 2010\u20132012 period","volume":"27","author":"Asencio M.\u00c1.","year":"2014","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0680","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.01760-09","article-title":"Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"54","author":"Auer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0685","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1155\/2013\/645018","article-title":"Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum \u03b2-lactamases from multiple regional Canadian hospitals","volume":"24","author":"Beuk","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0690","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00345-013-1031-5","article-title":"Increasing prevalence of ciprofloxacin resistance in extended-spectrum-\u03b2-lactamase-producing Escherichia coli urinary isolates","volume":"31","author":"Bonkat","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0695","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1742-1241.2012.02991.x","article-title":"Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum \u03b2-lactamase (ESBL)-producing enterobacteria","volume":"66","author":"Briongos-Figuero","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0700","first-page":"545","article-title":"Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum \u03b2-lactamase according to CLSI and EUCAST recommendations","volume":"48","author":"Ca\u011fan Akta\u015f","year":"2014","journal-title":"Mikrobiyol Bul"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0705","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkq051","article-title":"Fosfomycin susceptibility among extended-spectrum-\u03b2-lactamase-producing Escherichia coli in Nottingham, UK","volume":"65","author":"Chislett","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0710","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11255-015-1018-9","article-title":"Antimicrobial susceptibilities of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin","volume":"47","author":"Cho","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0715","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/j.ijid.2013.04.005","article-title":"Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey","volume":"17","author":"Demir","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0720","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkq286","article-title":"Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval","volume":"65","author":"den Heijer","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0725","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.medmal.2013.01.006","article-title":"Alternatives to carbapenems in ESBL-producing Escherichia coli infections","volume":"43","author":"Fournier","year":"2013","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0730","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/0974-2727.119849","article-title":"Determination of extended-spectrum \u03b2-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin","volume":"5","author":"Gupta","year":"2013","journal-title":"J Lab Physicians"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0735","first-page":"726179","article-title":"Detection of \u03b2-lactamases and outer membrane porins among Klebsiella pneumoniae strains isolated in Iran","volume":"2014","author":"Hashemi","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0740","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijantimicag.2010.12.003","article-title":"In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents","volume":"37","author":"Hsu","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0745","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijantimicag.2014.08.010","article-title":"Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China","volume":"45","author":"Jiang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0750","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.02399-13","article-title":"In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study","volume":"58","author":"Karlowsky","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0755","first-page":"914","article-title":"In vitro activity of fosfomycin tromethamine against extended spectrum \u03b2-lactamase producing urinary tract bacteria","volume":"24","author":"Khan","year":"2014","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0760","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1128\/AAC.00043-13","article-title":"Identification of extended-spectrum-\u03b2-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M \u03b2-lactamases in nonhospitalized patients","volume":"57","author":"Kopacz","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0765","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijantimicag.2014.05.020","article-title":"Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum \u03b2-lactamases and the role of fosfomycin","volume":"44","author":"Kresken","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0770","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-14-66","article-title":"In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004\u20132012)","volume":"14","author":"Lai","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0775","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/jac\/dks319","article-title":"Prevalence of acquired fosfomycin resistance among extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3","volume":"67","author":"Lee","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0780","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0785","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0790","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/mdr.2012.0263","article-title":"Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum \u03b2-lactamase","volume":"19","author":"Morf\u00edn-Otero","year":"2013","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0795","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4269\/ajtmh.2011.11-0057","article-title":"Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines","volume":"84","author":"Muvunyi","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0800","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jiac.2013.08.004","article-title":"Susceptibility of various oral antibacterial agents against extended spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae","volume":"20","author":"Nakamura","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0805","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/00365548.2012.734636","article-title":"High frequency of co-resistance in CTX-M-producing Escherichia coli to non-\u03b2-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden","volume":"45","author":"Ostholm Balkhed","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0810","doi-asserted-by":"crossref","first-page":"e004152","DOI":"10.1136\/bmjopen-2013-004152","article-title":"Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study","volume":"3","author":"Qiao","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0815","first-page":"43","article-title":"Increasing prevalence of fosfomycin resistance in extended-spectrum-\u03b2-lactamase-producing Escherichia coli urinary isolates (2005\u20132009\u20132011)","volume":"26","author":"Rodr\u00edguez-Avial","year":"2013","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0820","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajic.2014.06.013","article-title":"Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study","volume":"42","author":"Sorlozano","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0825","first-page":"36","article-title":"Changes in the antimicrobial susceptibility of Escherichia coli isolates from community diagnosed urinary tract infections during the period 2003-2007. Multicentre study in Castilla la Mancha (Spain)","volume":"23","author":"Tena","year":"2010","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0830","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1600-0463.2011.02766.x","article-title":"Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"119","author":"Titelman","year":"2011","journal-title":"APMIS"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0835","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.01834-09","article-title":"Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes","volume":"54","author":"Wachino","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0840","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/AAC.00589-13","article-title":"In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method","volume":"57","author":"D\u00edez-Aguilar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0845","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JCM.03484-13","article-title":"Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany","volume":"52","author":"Kaase","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0850","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/1471-2334-12-373","article-title":"Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese university hospital","volume":"12","author":"Li","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0855","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijantimicag.2014.01.021","article-title":"Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates","volume":"43","author":"Pena","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0860","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jiac.2014.10.009","article-title":"In vitro activity of potential old and new drugs against multidrug-resistant Gram-negatives","volume":"21","author":"Rizek","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0865","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jinf.2013.04.017","article-title":"Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil","volume":"67","author":"Tuon","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0870","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","article-title":"Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort","volume":"34","author":"Alexander","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0875","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.01235-09","article-title":"In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and\/or colistin","volume":"54","author":"Endimiani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0880","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0885","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jac\/dks364","article-title":"Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak","volume":"68","author":"Pa\u00f1o-Pardo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0890","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/AAC.02048-13","article-title":"Susceptibility of multiresistant Gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods","volume":"58","author":"Perdig\u00e3o-Neto","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0895","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00650-13","article-title":"Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans","volume":"57","author":"Johnson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0900","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0905","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/1471-2334-12-222","article-title":"Antibacterial resistances in uncomplicated urinary tract infections in women: ECO.SENS II data from primary health care in Austria","volume":"12","author":"Kamenski","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0910","first-page":"11","article-title":"Current efficacy of antibiotics against Klebsiella isolates from urine samples\u2014a multi-centric experience in Karachi","volume":"26","author":"Abdullah","year":"2013","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0915","doi-asserted-by":"crossref","first-page":"e103253","DOI":"10.1371\/journal.pone.0103253","article-title":"Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against Gram-negative clinical isolates in South India: a prospective study","volume":"9","author":"Rajenderan","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0920","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12088-011-0210-6","article-title":"Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey","volume":"52","author":"Aslan","year":"2012","journal-title":"Indian J Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0925","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.02.013","volume":"67","author":"Cuevas","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0930","first-page":"37","article-title":"Antimicrobial resistance in clinical patterns of Pseudomonas aeruginosa","volume":"25","author":"del Mar Casal","year":"2012","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0935","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.medmal.2010.03.002","article-title":"Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections","volume":"40","author":"Fabre","year":"2010","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0940","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2334-12-228","article-title":"Cefditoren: comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients","volume":"12","author":"Hatzaki","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0945","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2009.08.018","article-title":"Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment","volume":"35","author":"Katsarolis","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0950","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.medmal.2011.07.005","article-title":"French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy","volume":"42","author":"Neuzillet","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0955","doi-asserted-by":"crossref","first-page":"737","DOI":"10.20344\/amp.5352","article-title":"Evaluation of the antimicrobial susceptibility of community-acquired urinary tract infection","volume":"27","author":"Passadouro","year":"2014","journal-title":"Acta Med Port"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0960","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/AAC.00765-10","article-title":"Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location","volume":"55","author":"Sahuquillo-Arce","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0965","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/fmb.10.47","article-title":"Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials","volume":"5","author":"Samonis","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0970","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3346\/jkms.2014.29.8.1178","article-title":"Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea","volume":"29","author":"Seo","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0975","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bjid.2014.12.009","article-title":"Bacterial sensitivity to fosfomycin in pregnant women with urinary infection","volume":"19","author":"Souza","year":"2015","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0980","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/AAC.00663-12","article-title":"Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0985","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2012.07.023","article-title":"Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression","volume":"40","author":"Mavros","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0990","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib0995","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib1000","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1592\/phco.31.9.912","article-title":"Revisiting \u2018older\u2019 antimicrobials in the era of multidrug resistance","volume":"31","author":"Pogue","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib1005","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/AAC.47.9.2850-2858.2003","article-title":"Biological costs and mechanisms of fosfomycin resistance in Escherichia coli","volume":"47","author":"Nilsson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.001_bib1010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/00365549309008570","article-title":"Introducing fosfomycin for surgical prophylaxis\u2014emergence of resistance in aerobic faecal Gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures","volume":"25","author":"Olsson-Liljequist","year":"1993","journal-title":"Scand J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:56:59Z","timestamp":1567627019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0924857916000479"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726289273.793549922","asserted-by":"object"}]},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}